How did Labcorp's revenue and expenses trend in Q4 2024?

**Labcorp's Revenue and Expenses Trend in Q4 2024**:

1. **Revenue by Business Segments**:
- Clinical Diagnostics Laboratory: $10.14 billion
- Biopharma Laboratory Services: $2.92 billion
- Diagnostic Laboratories: $7.56 billion
- Intercompany Eliminations: -$5.8 million
2. **Net Income**: $143.6 million
3. **Comparison with Q3 and Q2 Results**:
- Q3 Sales: $3.28 billion, Net Income: $169.3 million
- Q2 Sales: $3.06 billion, Net Income: $183.3 million
4. **Analyst Expectations**:
- Expected Revenue: $3.26 billion, EPS: $3.48
- Actual Revenue: $3.28 billion, EPS: $3.50
5. **Segment Performance**:
- Biopharma Laboratory Services: Revenue $737.70 million, Adjusted Operating Income $120.90 million
- Diagnostics Laboratories: Revenue $2.55 billion, Adjusted Operating Income $387.40 million
6. **Strategic Developments and Factors**:
- Acquisitions and New Product Launches: Positive impact on revenue growth
- Weather-Related Disruptions: Negative impact on profitability

The data indicates that Labcorp's revenue was robust, with significant contributions from its Clinical Diagnostics Laboratory and Biopharma Laboratory Services segments. Despite intercompany eliminations showing a loss, the company's net income was positive, reflecting efficient management of its core operations. When compared to the previous quarter, there was a slight decline in net income but maintained strong revenue growth, which was slightly higher than analyst expectations. However, the impact of weather-related disruptions and intercompany adjustments highlighted the importance of considering external factors in understanding the company's financial performance.